₹219-292) to the Indian government and will be priced at double that rate in private market ones such sales open up.Pune-based SII's shot is a Recombinant Chimpanzee Adenovirus vector vaccine (Covishield), encoding the SARS-CoV-2 Spike (S) glycoprotein with technology transfer from AstraZeneca/Oxford University.On the other hand, Bharat Biotech has already produced about 20 million doses, Ella said, which will be increased to about 150 million before July or August.
The firm has previously said its vaccine -- that uses a dead version of the virus -- has efficacy rates of at least 60%, though it has yet to release detailed data.